PixarBio (PixarBio) Insider Ownership : 0.00 % (As of Jun. 16, 2024)

View and export this data going back to 2016. Start your Free Trial

What is PixarBio Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PixarBio's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PixarBio's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PixarBio's Float Percentage Of Total Shares Outstanding is 2.09%.

PixarBio Insider Ownership Historical Data

The historical data trend for PixarBio's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Insider Ownership Chart

PixarBio Annual Data

Trend

Dec14

Dec15

Insider Ownership

PixarBio Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Insider Ownership	Get a 7-Day Free Trial					-	-	-	-	-

PixarBio Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

PixarBio (PixarBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155

Website

https://www.pixarbio.com

PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.